Market Access and Reimbursement Risk Assessment.
Built by former payers, HTA reviewers, and Industry Experts.
Learn how MARA Rating’s Uncertainty & Sensitivity domain (A++–C) predicts HTA outcomes; why 2.6 vs 2.0 scores sway payer trust, pricing & reimbursement. Since 2020, we’ve seen a clear split:
Many breakthrough therapies in the U.S. stumble in their first year on the market, despite strong clinical promise. The reason isn’t usually safety or efficacy. It’s cost pressures, evidence maturity, and system
About MARA Rating: We provide an independent Market‑Access Risk Assessment (A++ → C) built on a transparent, 10‑domain HTA framework. Use the score to benchmark an asset’s access prospects against
MARA Rating’s Care Pathway Integration score (A++–C) predicts HTA endorsement and payer adoption by measuring clinical guideline alignment, workflow efficiency, administration ease, and implementation feasibility. Too often, M&A teams under-weight
MARA Rating in the Workflow: How Market Access & BD Teams Use It to Make Better Asset Calls (MARA Rating stands for Market Access Risk Assessment Rating.) Most valuations overweight
Independent MARA® Ratings quantify HTA reimbursement risk for pharma assets. 5-year 97% precision across 10 domains. Request your report today. MARA Rating Insight Since 2020, assets averaging a 2.9 Comparator Selection score sailed
Every payer’s checklist is different. This week: Health-Related Quality of Life—how patient experience shapes coverage. MARA Rating Insight: Since 2020, drugs averaging a 2.8 HRQoL score secured reimbursement far more often than those
A concise overview of the essential Health Technology Assessment domains every drug developer must address. Use this checklist to design and execute development programs that directly address payer needs across
Market Access Risk Assessment MARA Rating Company Obesity drives ≈ $173 billion in direct U.S. medical costs each year (2019 USD). Four next‑generation pipeline assets—Survodutide, Retatrutide, Orforglipron and the amylin/GLP‑1 co‑formulation Cagrilintide + Semaglutide (“CagriSema”)—promise weight‑loss efficacy
Breaking the Bias: Why Market-Access Teams Must Avoid Common Thinking Traps in Pharma Acquisitions Many M&A teams do not pay enough attention to market-access risks. Yet simple thinking errors on